Compare TELA & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TELA | QTTB |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.5M | 44.3M |
| IPO Year | 2019 | 2018 |
| Metric | TELA | QTTB |
|---|---|---|
| Price | $0.74 | $6.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $3.31 | ★ $13.00 |
| AVG Volume (30 Days) | 56.4K | ★ 177.3K |
| Earning Date | 01-01-0001 | 06-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 34.80 | ★ 136.78 |
| EPS | N/A | ★ 2.42 |
| Revenue | ★ $69,300,000.00 | $53,737,000.00 |
| Revenue This Year | $18.41 | N/A |
| Revenue Next Year | $15.20 | N/A |
| P/E Ratio | ★ N/A | $2.91 |
| Revenue Growth | ★ 18.56 | N/A |
| 52 Week Low | $0.67 | $1.38 |
| 52 Week High | $2.48 | $7.65 |
| Indicator | TELA | QTTB |
|---|---|---|
| Relative Strength Index (RSI) | 42.67 | 76.03 |
| Support Level | $0.67 | $3.75 |
| Resistance Level | $1.20 | N/A |
| Average True Range (ATR) | 0.08 | 0.60 |
| MACD | 0.00 | 0.24 |
| Stochastic Oscillator | 34.38 | 73.55 |
TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.